• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Impact Factor leap for Psychiatry Karger journal — home of innovation

Bioengineer by Bioengineer
July 6, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

According to the Journal Citation Reports (JCR) recently released by Clarivate Analytics, the Impact Factor of the Journal Psychotherapy and Psychosomatics has increased from 8.964 to 13.122 in 2017. This takes the rank of the journal to the fifth position of 142 journals in total in the subject area Psychiatry of the SCI.

"This journal is a home for innovation. We focus on choosing articles for the journal that represent new ideas," is the explanation of Editor-in-Chief Professor Giovanni Andrea Fava for this significant improvement. Over the last few years, Psychotherapy and Psychosomatics has anticipated and developed new lines of research in psychosomatic medicine, psychotherapy research and psychopharmacology. The journal features editorials and reviews on current and controversial issues at the interface between medical and behavioral sciences.

"For Psychotherapy and Psychosomatics, we have decided to give priority to submissions of high methodological quality that may provide new clinical insights. Of course, not every idea is followed by developments and gains acceptance. But we are happy to take a chance. I am thankful for the freedom and the trust of our publishing house," emphasizes Fava.

"Primarily, the increase of the Impact Factor of Psychotherapy and Psychosomatics reflects the excellent job of our Editor-in-Chief Giovanni Fava and the editorial board for this journal," says Gabriella Karger, Vice Chairwoman and Publisher.

The journal was founded in 1953 as Psychotherapeutica et Psychosomatica by E.A.D.E. and continued in 1965 as Psychotherapy and Psychosomatics at Karger Publishers. Giovanni Andrea Fava has been Editor-in-Chief of the journal since 1992.

###

About Karger Publishers

Karger Publishers in Basel, Switzerland, is a globally active medical and scientific publishing company. Independent and family-run in the fourth generation by Vice Chairwoman and Publisher Gabriella Karger and Chairman Thomas Karger, the company is dedicated to serving the information needs of the scientific community with publications of high-quality content, covering all fields of medical science. The publication program comprises 50 new books per year and 108 peer-reviewed journals with a growing number of open access publications. Karger content is published predominantly in English, with a strong focus on basic and clinical research, and is generally available online. S. Karger AG consists of the publishing company Karger Publishers (est. 1890) and the International Subscription Agency Karger Libri (est. 1960).

Further information about Karger Publishers: http://www.karger.com

Media Contact

Sophie Saberi
[email protected]
41-613-061-352
@KargerPublisher

http://www.karger.com

Share12Tweet8Share2ShareShareShare2

Related Posts

Neg-Entropy: The Key Therapeutic Target for Chronic Diseases

February 7, 2026

Multidisciplinary Evidence-Based Guidelines for Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

February 7, 2026

Early Tuberculosis Treatment Lowers Sepsis Mortality in People with HIV

February 7, 2026

Structure-Guided Development of Picomolar Macrocyclic Inhibitors Targeting TRPC5 Channels with Antidepressant Effects

February 7, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Neg-Entropy: The Key Therapeutic Target for Chronic Diseases

Multidisciplinary Evidence-Based Guidelines for Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

Early Tuberculosis Treatment Lowers Sepsis Mortality in People with HIV

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.